Volume 12, Number 8—August 2006
Research
Antibody Response to Pneumocystis jirovecii
Kieran R. Daly*†, Laurence Huang‡, Alison Morris§, Judy Koch*†, Kristina Crothers‡¶, Linda Levin†, Shary Eiser‡, Supriya Satwah†, Patrizia Zucchi‡#, and Peter D. Walzer*†
Table 3
Antibody levels to major surface glycoprotein C in Pneumocystis pneumonia (PCP) patients by history of PCP and week of observation*
| Week | No history of PCP |
History of PCP |
||
|---|---|---|---|---|
| n | Geometric mean (95% CI) | n | Geometric mean (95% CI) | |
| Baseline (0) | 59 | 4.1 (2.8–6.0) | 19 | 4.2 (2.0–9.0) |
| 1–2 | 18 | 9.9 (4.6–21.5) | 6 | 3.9 (0.5–30.8) |
| 3–4 | 11 | 17.9 (5.9–53.6)† | 6 | 3.0 (0.7–12.1) |
| 5–6 | 13 | 4.4 (2.6–7.4) | 4 | 1‡ |
*n = no. patients who were observed at the specified follow-up time and at baseline. CI, confidence interval.
†p<0.001 versus week 0.
‡Observed values were equal.
